...
>Other IgG-like molecules to be included based on absence of technical limitations
Approach:
<Link to Meeting Minutes>
>Collate PK on approx. 10 priority marketed Ab drugs which are know to have high quality published data and check whether this meets the above 'gold standard' definition.
>Propose 'data quality' tiers into which data from published molecules can be placed.: Link to PK quality tiers page
>Collate PK and other data from additional Ab molecules and fit these into proposed 'quality tiers'
...
>Once we have identified molecules in each Tier can we characterise these from a biophysical perspective and see whether there are correlations between PK and early dataLink to PK quality tiers page
Further needs:
-Discussion on sources of data e.g. Jain et al., (2017) publication, FDA drug approval packages
...